Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week Phase II PoC trial of BI 730357 in active ankylosing spondylitis
2019-001684-77Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA) comparing BI 730357 with Placebo (2 arms). Primary endpoint: ASAS40 response at Week 12. Started Dec 2020; status: terminated.
02
Drugs
bevurogant
03
Conditions
ankylosing spondylitis (AS)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2019-001684-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001684-77.